“Safety and Adverse Events of Special Interest in 825 Adults With Atopic Dermatitis Receiving Up to 12 Months of Tralokinumab Treatment in a Real-World Setting” (2026) SKIN The Journal of Cutaneous Medicine, 10(2), p. s730. doi:10.25251/7mx6d484.